A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).

NCT Number	NCT07053345
Lead Sponsor	Janssen Korea, Ltd., Korea
Conditions	Depressive Disorder, Treatment-Resistant
Enrollment	47 participants
Start Date	2025-06-09
Primary Completion	2027-06-25 (estimated)
Study Completion	2027-06-25 (estimated)
Updated on ClinicalTrials.gov	2026-06-05